INTRODUCTION
Over the last 5 years osteoporosis has been recognized as a complication of cystic fibrosis (CF)1. Both paediatric and adult CF physicians must now consider the skeletal health of their patients. Failure to do so will result in unnecessary fractures and a reduced quality of life ( Figure 1 ). This article examines the likely aetiological factors in the development of CF osteoporosis, explains how the diagnosis can be established, documents the prevalence, and discusses the therapeutic options. DEFINITION Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture risk2.
RELATIONSHIP OF BONE MASS TO FRACTURES
There is strong evidence that fractures result from low bone mass. This is because bone mineral density (BMD) accounts for 750/o-85% of the variance in the ultimate strength of bone tissue3. BMD is a function of the amount of bone accreted at the time peak bone mass is achieved, and that which is resorbed (for example, after the menopause or during the course of disease). In the normal population, bone mass increases during childhood, particularly at the time of the adolescent growth spurt, to reach a peak bone mass between the ages of 25 to 35 years. Bone mass then falls gradually in both sexes, with a period of accelerated bone loss in women around the time of the menopause (Figure 2)4.
In CF patients it is not clear whether reduced bone density results from reduced bone accretion in early life, from increased bone loss in later life, or from a combination of the two.
DETERMINANTS OF BONE FORMATION AND PEAK BONE MASS Genetic
Genetic factors are influential in determining bone mass in the general population5. Up to 80% of the variance in bone density may be genetically determined6. Polymorphisms of the vitamin D receptor gene have been reported to correlate with BMD, as have polymorphisms of the oestrogen receptor and IL-6 receptor genes7-9. It is not known whether the CF transmembrane regulator (CFTR) protein is expressed in normal bone. If it is, then CF osteoporosis may be a consequence of the gene defect, with the following risk factors being contributary: young women18-20. Exercise programmes can lead to significant increases in bone mass21'22. Individuals who are immobilized lose bone mass rapidly; thus during periods of ill health, CF patients are likely to resorb bone. CF patients should therefore be encouraged to exercise on a regular basis in order to improve their BMD. In addition, they will benefit from the other well documented effects of exercise in CF23'24.
Hormonal factors (b)
A constitutional delay in puberty results in reduced bone density in otherwise normal adult men25. Malnutrition, a major cause of pubertal delay, may explain the high incidence of pubertal delay and osteopenia in CF adolescents26. The better nutrition provided to CF adolescents in recent years may result in improved sexual and skeletal maturation. Should puberty be delayed, testosterone is a safe and effective means of improving growth rate in male adolescents27.
Hypogonadism is common in CF and is associated with low bone mass28.
with an increased risk of osteoporosis in later lifeI1. The effect of calcium supplementation on BMD is controversial, but it has been suggested that calcium supplementation enhances the rate of increase in BMD in prepubertal children12.
In CF patients, vitamin D malabsorption secondary to pancreatic insufficiency and biliary disease may have a negative effect on calcium absorption and bone home--ostasis. Recent data suggests that calcium absorption from the gut is reduced in CF patients, even when pancreatic enzyme supplements are used13. The current literature documenting vitamin D levels in CF patients is very inconsistent. Some studies have reported normal and others reduced vitamin D levels1 l7. On the whole, studies have failed to demonstrate convincing evidence of a correlation between low vitamin D levels and reduced BMD. These apparent differences in the literature may be explained by different assay methods, differences in disease severity between the study populations, different daily vitamin supplementation, and differing levels of exposure to sunlight. These inconsistencies highlight the need for further research into this area involving a larger number of patients.
Physical activity
Physical activity, particularly weight bearing activity, is an important determinant of bone mass. Levels of physical activity correlate with BMD in children, adolescents and
DETERMINANTS OF BONE LOSS
In the general population bone loss is thought to commence in both sexes in the 30s. In healthy men the rate of bone loss is approximately 30/5% per decade. In women, bone loss before the menopause is small and probably parallel to that of men. After the menopause there is a period of accelerated bone loss, averaging 2% per year over the next 5-10 years, and thereafter declines in rate29.
At present few CF females reach the menopause. For both male and female CF patients, nutritional deficiencies, lack of exercise, hypogonadism, genetic factors, low mean body mass, diabetes, cyclosporin therapy, and glucocorticoid therapy are likely to be more important determinants of bone loss.
A CF specific determinant of bone loss may be disease severity. A possible negative effect of disease severity on BMD may be mediated by its effects on body weight, as chronic pulmonary and pancreatic disease leads to greater degrees of malnutrition. Additionally, release of cytokines such as tumour necrosis factor-oc, transforming growth factor-,B, interleukin-1 and interleukin-6, in response to chronic pulmonary sepsis, may also increase bone resorption30.
ASSESSMENT OF BONE DENSITY
Bone density is measured at those anatomical sites where fractures commonly occur, and several techniques can be used. Single and dual energy X-ray absorptiometry (SXA and DXA) SXA is usually employed to measure BMD at the forearm, and DXA can determine BMD in the proximal femur (femoral neck, trochanter, Ward's area), lumbar spine, forearm and whole body. These scanning techniques are quick, relatively cheap and involve a very small radiation exposure (<1 pSV per site). The disadvantage of SXA and DXA is that they provide projectional (g/cm2) rather than true volumetric density values (g/cm3). This is important in CF patients whose bones may be smaller than those of the average population. Bone mineral apparent density is a size adjusted BMD value and may be more appropriate for CF patients28.
Quantitative computed tomography (QCT) QCT is most commonly used to scan the lumbar spine and is a measure of trabecular BMD. QCT gives a true volumetric density (g/cm3) in contrast to DXA and SXA.
The disadvantages of QCT are the cost and higher radiation exposure (approximately 50-100 ,ISV) than DXA. It is also less precise than DXA but may be more sensitive in detecting changes in BMD over time.
Ultrasound and magnetic resonance These techniques are currently research tools and are seldom used in routine clinical practice. Both techniques benefit from not using ionizing radiation. Compared to DXA, SXA and QCT, ultrasound and magnetic resonance scanning provide more information about the quality of bone architecture in addition to the bone density.
Results
BMD results are traditionally reported as Z or T scores. The T score is the number of standard deviations (SDs) that a BMD value lies away from the mean of a control population of young adults who have achieved their peak bone mass. T scores are most commonly used to identify bone loss after the menopause and to determine fracture risk.
A Z score is the number of SDs that a BMD value lies away from the mean of an age and sex matched control population. Z scores are potentially more useful in assessing bone density in CF patients because the majority have not yet reached their peak bone mass.
DIAGNOSIS
The basis for the diagnosis of osteoporosis is the precise measurement of BMD with non-invasive radiological techniques. The relationship between bone mineral density and fracture risk is well established: as BMD fails, the risk of fracture rises.
The World Health Organization has proposed a classification system for women based on three diagnostic categories of bone density, measured relative to the population mean in young adults (T scores)31. I Normal, in which bone mineral density values lie at a threshold set at one SD below the mean 2 Osteopenia, in which values are between 1.0 and 2.5 SDs below the mean 3 Osteoporosis, where values are greater than 2.5 SDs below the mean.
The risk of fracture approximately doubles for each SD decrease in BMD below the mean of peak bone mass.
It is tempting to apply this diagnostic system to CF patients, but as discussed above, it applies only to women and is based on T scores, which are not appropriate for most CF patients.
PREVALENCE OF OSTEOPOROSIS IN CF PATIENTS
Several studies from the UK, USA and New Zealand have documented low bone mass and fragility fractures in both paediatric and adult CF patients28'30'32 40. The most informative are reviewed in the following paragraphs.
Bhudhikanok, in a study of 49 CF patients with a mean age of 20.6 years, demonstrated that mean BMD Z scores were -1.7 at the lumbar spine, and -1.9 at the femoral neck. Age, pubertal stage, body mass, caloric expenditure, illness severity, glucocorticoid therapy and gonadal function predicted bone mineral status28.
Aris studied the BMD of 60 CF patients (mean age 28) who had severe pulmonary disease (mean forced expiratory volume (FEV1) 34% of predicted). The mean BMD Z scores at the spine and femur were -2.17 and -2.02, respectively. In this study only bone mass index (BMI) and cumulative prednisolone dose were associated with low BMI32.
Henderson documented significantly reduced bone mass in his study of CF children and adolescents36. 62 patients (mean age 10.7 years) had mean BMD Z scores of -1.03 at the lumbar spine and -0.71 in the proximal femur. These values correlated well with body weight and FEV1. Preliminary data from the Manchester Adult CF unit demonstrates that in a study of 80 CF patients [M=F, mean (SD) age 26 years (7.6), FEV1 % predicted 54.8 (21.5), BMI 20.8 (2. 2)], that bone density was significantly reduced40. Bone density was measured at the distal and ultra distal forearm sites using SXA (Osteometer DTX-100) and at lumbar spine and proximal femur using DXA (Hologic QDR 4500). The mean BMD Z scores were -0.76 at the distal forearm, -0.39 at the ultra distal Voltime 91 Supplement No, 34 1 9 9 8 forearm, -1.28 at the lumbar spine and -1.12 at the hip. 37.5% of patients had a Z score lower than -2.
Direct comparisons between studies is difficult because patients of different ages and illness severities are involved, and they have had BMD measurements performed at different sites using different techniques. In terms of documenting the natural history and aetiology of osteoporosis in CF patients, longitudinal rather than cross-sectional studies are required.
OSTEOPOROSIS AND LUNG TRANSPLANTATION
Osteoporosis is reported in all patient groups after lung transplantation. The BMD of cystic fibrosis patients prior to and after transplantation is lower than that in any other Only a fraction of CF patients are postmenopausal and so traditional HRT preparations are unsuitable. However, hormonal manipulation in those patients who are experiencing pubertal delay or are hypogonadal may be appropriate.
Calcitriol, a naturally occurring vitamin D metabolite, is a logical choice for treating osteoporosis in CF patients as long as adequate doses are used to overcome the characteristic malabsorption of fat soluble vitamins. Unfortunately, the results of trials involving calcitriol are inconsistent, and the major trial supporting the use of calcitriol in the treatment of established postmenopausal osteoporosis showed that it prevented an increase in fracture rate rather than demonstrating an actual decrease in fracture rate43. In addition, the only evidence for fracture reduction was in the spine and not elsewhere in the skeleton.
Bisphosphonates are effective in the treatment of established postmenopausal and corticosteroid induced osteoporosis44 47. They reduce bone resorption by arresting osteoclastic activity. A recent study suggests that increased bone resorption is the major factor resulting in reduced bone mass in CF patients48. Bisphosphonates may therefore be the most appropriate treatment for CF osteoporosis. However, they do have some inherent disadvantages for use in patients with CF. Intestinal absorption is approximately 1-2% in the normal population and so may be further reduced in patients with CF. In addition, the gastrointestinal (GI) intolerance and oesophageal ulceration caused by some bisphosphonates may be more prevalent in CF patients who frequently suffer from oesophageal reflux49. A means to circumvent the problems of GI malabsorption and intolerance may be to administer the bisphosphonate intravenously. Intravenous pamidronate has been shown to be effective in the treatment of both postmenopausal and corticosteroid osteoporosis50Q51. The long-term effects of bisphosphonates administered to those that are still growing is not yet fully established.
Whilst there are no published trial data, low bone mass can hopefully be prevented by encouraging good nutrition, adequate calcium and vitamin D supplementation, normal pubertal development, frequent weight bearing exercise and minimizing glucocorticoid use. Once established, osteoporosis should perhaps be treated with bisphosphonates. SUMMARY * Osteoporosis is prevalent in adults with CF * Longitudinal data have not been collected and so the natural history is unknown * The aetiology is not known * There are no published randomized controlled trials evaluating treatments for osteoporosis in CF patients.
